TARA - NASDAQ
Protara Therapeutics, Inc.
$4.22
-1.2%Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
At a Glance
Live SnapshotNo Revenue Data
TARA has not reported any revenue values in the available annual periods.
Protara Therapeutics, Inc. Profit Bridge
Profitability Analysis
Protara Therapeutics, Inc. Income Statement
TARA • NASDAQ
| Protara Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.9M | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||||||
(362K) | (0.0) | (341K) | (0.0) | (0.0) | (196K) | (16K) | (115K) | (148K) | (123K) | (57K) | (0.0) | (27K) | (57K) | |
-362K | 0.0 | -341K | 0.0 | 0.0 | -196K | -16K | -115K | -148K | -123K | -57K | 2.9M | -27K | -57K | |
OPERATING INCOME | ||||||||||||||
(64.2M) | (49.2M) | (43.3M) | (67.1M) | (47.5M) | (34.2M) | (15.3M) | (26.1M) | (30.2M) | (28.6M) | (20.8M) | (10.5M) | (7.1M) | (7.9M) | |
(21.9M) | (17.5M) | (18.6M) | (20.7M) | (26.4M) | (22.4M) | (8.8M) | (10.6M) | (8.5M) | (9.7M) | (8.4M) | (4.1M) | (3.1M) | (2M) | |
(42.6M) | (31.7M) | (24.8M) | (16.8M) | (21.1M) | (11.9M) | (6.4M) | (15.5M) | (21.7M) | (18.9M) | (12.4M) | (6.4M) | (4M) | (5.9M) | |
-64.5M | -49.2M | -43.6M | -67.1M | -47.5M | -34.4M | -15.3M | -26.1M | -30.4M | -28.7M | -20.9M | -7.6M | -7.1M | -8M | |
PRE-TAX INCOME | ||||||||||||||
(0.0) | (0.0) | (0.0) | (1.1M) | (1.7M) | (34K) | (0.0) | (0.0) | (259K) | (193K) | (144K) | (857K) | (861K) | (0.0) | |
6.3M | 4.1M | 2.7M | -27K | -1.5M | 432K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -857K | 20K | |
-362K | (0.0) | -137K | (29.5M) | (0.0) | (0.0) | (0.0) | (207K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
7.1M | 4.6M | 3.2M | 1.1M | 237K | 466K | 0.0 | 643K | 398K | 179K | -507K | 4.2M | -790K | 26K | |
-57.4M | -44.6M | -40.4M | -66M | -47.3M | -34M | -15M | -25.4M | -30M | -28.5M | -21.4M | -3.3M | -7.9M | -8M | |
NET INCOME | ||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -262K | (5.4M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-57.4M | -44.6M | -40.4M | -66M | -47.3M | -34M | -15M | -25.4M | -30M | -28.5M | -21.4M | -3.3M | -7.9M | -8M |
SEC Filings
TARA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
S-3 S-3 N/A | May 14, 2026 | May 14, 2026 | ||
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 30, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 23, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 15, 2025 | December 15, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 04, 2025 | 2025 |
Related Guides
Continue your TARA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.